Vitamin B2,
does it really help with Intrahepatic fat in adults with metabolic dysfunction-associated fatty liver?
research showsThe search documented through 2026-09-16 did not verify a directly eligible result establishing that oral vitamin B2 alone reduces intrahepatic fat in adults with metabolic fatty liver. Human dietary/supplement observations and multicomponent trials exist, but they do not isolate B2’s effect. This is neither a finding of no effect nor a claim that human research is absent.
ads claimThis report does not support a fixed percentage liver-fat reduction from B2, treating enzyme changes as fat removal, or attributing combination effects to B2. This is not a claim to have audited all advertising.
Four separate assessment dimensions
| Effect direction and size | The search documented through 2026-09-16 did not verify a directly eligible result establishing that oral vitamin B2 alone reduces intrahepatic fat in adults with metabolic fatty liver. Human dietary/supplement observations and multicomponent trials exist, but they do not isolate B2’s effect. This is neither a finding of no effect nor a claim that human research is absent. |
|---|---|
| Evidence certainty | No directly eligible result verified in the documented search, not a finding of no effect or global absence of human research. |
| Applicability | Adults, isolated oral B2 and liver fat only. Deficiency correction versus additional supplementation, historical NAFLD versus current MASLD, and imaging fat versus enzymes remain distinct. |
| Safety | Comparative safety for an exact B2-only dose and duration in this population is unknown. NIH distinguishes the absence of an established upper intake level from demonstrated harmlessness at high intake. Combination adverse events were not attributed to B2 alone. Pregnancy, childhood, renal impairment, severe liver disease, long-term exposure, polypharmacy and assay interference remain unverified for this question. Research doses are not dosing recommendations. [S04, S07] |
? has no numerical score. Calculator C from invalid inputs is rejected. Chamgap is not official GRADE or treatment-success probability.
Useful facts when choosing a product
- The selected intervention is single-ingredient oral B2. Riboflavin butyrate, FMN and FAD were not assumed clinically interchangeable because of related names.
- The 2.4 mg/day in S04 is B2 contained in a combination. It is not an established effective B2-only dose or personal dosing instruction.
Chamgap Semantic Classification Code
Permanent code issued
S.riboflavin.oral-single-active-regimen-unverified.adults-metabolic-fatty-liver-liver-fat.reduce.placebo-background-care-unverifiedSubstances > Riboflavin > Oral single-active regimen unverified > Liver fat in adults with metabolic fatty liver > Reduce > Placebo/background comparison unverified
Published as current value ? with no numerical score and unknown safety. An unverified directly eligible B2-alone liver-fat effect is distinguished from the existence of adjacent human research; new evidence triggers revision. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Single-active oral riboflavin (vitamin B2) |
| Source or part used | Isolated chemical: anatomical part not applicable; manufacturing origin and purity unverified |
| Formulation or processing | Single-active oral riboflavin; salts, derivatives and release profiles not presumed equivalent |
| Route | Oral |
| Dose | No directly eligible B2-alone dose established |
| Duration | No directly eligible B2-alone duration or primary time point established |
| Population | Adults with metabolic fatty liver; historical NAFLD eligibility not automatically converted to current MASLD |
| Effect or condition | Reduction in intrahepatic fat |
| Primary endpoint | Between-group liver fat; MRI-PDFF, CT/CAP, enzymes and fibrosis kept distinct |
| Comparator | Proposed placebo/usual care/appropriate active control with equal background care; actual directly eligible comparison unverified |
| Duplicate-detection key | R01|vitamin-B2|oral|LIVER|adults-metabolic-fatty-liver |
What the research actually shows
Both the liver-fat endpoint and the B2-only intervention must be preserved. Dietary associations, combinations, liver enzymes and animal deficiency findings were not merged into a B2 treatment effect. Li studied dietary and supplement exposure rather than assigned B2 treatment; CORONA tested a carnitine-orotate complex. Metaclear also contains many ingredients besides B2. A registered MRI-PDFF measurement plan is not a verified treatment result. [S01–S05] Primary articles, abstracts and official registry indexed excerpts were distinguished by access level. No directly eligible isolated B2 effect result was verified; related human observational, combination and preclinical evidence was retained separately.
Why this is classified as ?
Efficacy grade and score remain unassigned. Clinical claim B and surrogate endpoint S are identifiable, but the remaining isolated-intervention axes lack support. Related human endpoint research prevents asserting no_human_study=true. The calculator’s mechanical C on invalid inputs was not adopted.
Counterpoint. A nonsignificant observational interval does not establish equivalence or no effect. Conversely, a positive association or combination benefit does not establish an isolated ingredient’s causal effect.
Rejudgment record. No directly eligible effect verified; efficacy unscored — Supplied grading rules and actual calculator diagnostics; unknown axes not invented
Review performed and remaining limitations
Direct effect, CI, MCID, dose, duration and target safety remain unknown. Some full texts, supplements and native registry results/history were inaccessible; participant-flow and combination-trial blinding conflicts were retained.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Li 2023 | Cross-sectional / 668 postmenopausal women; Highest versus lowest quartile of food + supplement intake | Cross-sectional / 668 postmenopausal women | First Hospital of Jilin University / Jilin Provincial Health Special Project reported | Presence of CAP-defined steatosis | Model 3 OR 0.53 (95% CI 0.24–1.16). Not assigned B2 treatment or liver-fat percentage change. | Retained as adjacent/excluded evidence, not used to score isolated B2 target efficacy |
| Vahid 2019 | Case-control observation / 295 cases, 704 controls; Food-frequency-questionnaire nutritional-quality index | Case-control observation / 295 cases, 704 controls | Funding not verified: Full-text funding statement not accessed | NAFLD case status | Abstract OR 0.49 (95% CI 0.28–0.78); direction wording and exact contrast need full-text context. | Retained as adjacent/excluded evidence, not used to score isolated B2 target efficacy |
| CORONA 2015 | Randomized combination trial / 78 participants, 12 weeks; Carnitine-orotate complex versus placebo | Randomized combination trial / 78 participants, 12 weeks | Funding not verified: Funding statement not verified; commercial R&D author affiliation is confirmed | ALT normalization primary; CT attenuation secondary | Favorable CT result reported for the complex; B2 contribution not isolated. | Retained as adjacent/excluded evidence, not used to score isolated B2 target efficacy |
| Metaclear 2019 | Combination trial / 80 participants, 3 months; Multicomponent tablets containing B2 versus placebo | Combination trial / 80 participants, 3 months | Metagenics Europe Ltd., Belgium supplied the product; other funding not confirmed | Liver enzymes and calculated HSI/FLI indices | B2 content 2.4 mg/day is within a combination, not a direct imaging fat fraction or isolated effect. | Retained as adjacent/excluded evidence, not used to score isolated B2 target efficacy |
| NCT06152991 | Trial registration / final sample and results unverified; Godex complex versus placebo | Trial registration / final sample and results unverified | Funding not verified: not established in accessed records | MRI-PDFF plan in indexed registry material | Native results/history inaccessible. A measurement plan is not an observed benefit. | Retained as adjacent/excluded evidence, not used to score isolated B2 target efficacy |
| Wang 2024 | Mouse/cell preclinical study; B2 deficiency and high-fat conditions | Mouse/cell preclinical study | Funding not verified: not established in accessed records | Experimental hepatic lipid accumulation | Not generalized to additional B2 supplementation in humans. | Retained as adjacent/excluded evidence, not used to score isolated B2 target efficacy |
Receipt — 10 References
Evidence access cutoff: 2026-09-16. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-16 · Corrections: none
Cite this verdict
[Chamgap] Does oral vitamin B2 alone reduce liver fat in adults with metabolic fatty liver? — Evidence Grade ?. 10 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/oral-riboflavin-adults-metabolic-fatty-liver-intrahepatic-fat/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.